Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Oct 20 - Oct 25
S-Acetyl Glutathione
To do this, the body must be able to recycle glutathione
In summary: Survodutide (BI 456906) is an investigational GCGR/GLP-1 dual agonist being developed globally by Boehringer Ingelheim (under license from Zealand Pharma), now in Phase 3 for obesity with compelling Phase 2 weight-loss data that support its differentiation from existing GLP-1 therapies and strong potential across cardiometabolic indications
References Kumar M, Sarma DK, Shubham S, Kumawat M, Verma V, Prakash A, Tiwari R
US$ 22.91
US$ 26.49
US$ 23.83
US$ 21.68
US$ 26.30
